Oct 28, 2024
Eli Lilly’s GLP-1 drug Mounjaro receives Hong Kong approval for treating obesity and associated health problems like type 2 diabetes. (Source)
Ironwood Pharmaceuticals highlights positive Phase 3 data for its GLP-2 peptide, apraglutide, in treating short bowel syndrome, aiming to bolster investor confidence. (Source)
Oct 24, 2024
Novo Nordisk’s semaglutide, a GLP-1 agonist, could be a game-changer in the fight against Alzheimer’s disease. (Source)
Oct 23, 2024
Viking Therapeutics speeds up development of obesity drug VK2735. (VK2735 is a dual agonist of the GLP-1 and GIP receptors.) (Source)
Oct 21, 2024
Noom and Waltz Health partner to offer employers cost-effective GLP-1 access through virtual obesity management. Virtual health, GLP-1, obesity (Source)
Oct 16, 2024
Neurogastrx reports promising results from its phase I clinical trial of NG101. The investigational drug demonstrated significant efficacy in reducing nausea and vomiting associated with GLP-1 agonist medications. (Source)
Gan & Lee Pharmaceuticals’ bi-weekly GLP-1 receptor agonist, GZR18 injection, outperforms semaglutide (Ozempic®) in reducing HbA1c and body weight in patients with Type 2 diabetes. This was demonstrated in a Phase 2 clinical study after 24 weeks of treatment. (Source)
Oct 03, 2024
England’s National Health Service (NHS) will provide Eli Lilly‘s weight-loss medication, Mounjaro, to nearly 250,000 individuals over the next 3 years. This decision, announced by the country’s drugs cost regulator, aims to help obese people with at least 3 weight-related health conditions. (Source)
Oct 01, 2024
Kailera Therapeutics, a newly formed company with $400 million in funding, aims to combat obesity and related conditions. The company has acquired four assets from Jiangsu Hengrui Pharmaceuticals, including its lead clinical program, KAI-9531. KAI-9531, an injectable dual agonist targeting GLP-1 and GIP receptors, has shown promising results in Phase 2 clinical trials for both obesity and type 2 diabetes. (Source)
Sept 26, 2024
Biocon collaborates with Tabuk Pharmaceuticals for GLP-1 product commercialization in the Middle East. (Source)
Sept 24, 2024
Semaglutide, GLP-1RA drug by Novo Nordisk, used for obesity, has shown potential in treating Hidradenitis Suppurativa (chronic skin condition) in people with obesity, according to a study presented at the EADV Congress. (Source)
Semaglutide (Novo Nordisk) demonstrated an association with a decreased risk of opioid overdose among individuals with type 2 diabetes and opioid use disorder, suggesting its potential therapeutic efficacy in preventing overdoses. (Source)
Sept 19, 2024
Wegovy® (semaglutide 2.4 mg), developed by Novo Nordisk, is the first obesity medication to gain European regulatory approval for improving heart failure symptoms and physical function in patients with obesity-related HFpEF. (Source)
Sept 16, 2024
New Scientific Study: GLP-1 RA use reduced the risk of cirrhosis progression and mortality in patients with MASLD and diabetes. (Source)
